RefID Author Title Journal RefYear MedlineID Published 64 Condra, JH Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996 8970946 Yes 67 Winters, MA Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. AAC 1997 9087484 Yes 69 Shafer, RW Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol 1997 9188616 Yes 72 Shafer, RW Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1 - infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 1995 7541064 Yes 113 Fitzgibbon, JE Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine. AAC 1992 1317143 Yes 141 Molla, A Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996 8673921 Yes 168 Shafer, RW Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998 9634429 Yes 173 Shafer, RW Sequence and drug susceptibility of HIV-1 type C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. ARHR 1999 10024054 Yes 176 Markowitz, M A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis 1998 9607830 Yes 177 Winters, MA Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J Virol 1998 9573309 Yes 410 Dueweke, TJ A mutation in reverse transcriptase of bis(heteroaryl)piperazine- resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. PNAS 1993 7685109 Yes 483 Jacobsen, H Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995 7831807 Yes 497 Kellam, P Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994 7509370 Yes 520 Lacey, SF Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'- dideoxythymidine in cell culture. AAC 1994 7522429 Yes 524 Larder, BA Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 1993 7692302 Yes 555 Mellors, JW Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. AAC 1995 7542860 Yes 580 Patick, AK Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. AAC 1996 8834868 Yes 631 Shirasaka, T Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. PNAS 1995 7534421 Yes 640 St Clair, MH Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991 1716788 Yes 649 Tisdale, M Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. PNAS 1993 7685907 Yes 705 Patick, AK Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. AAC 1998 9756769 Yes 711 Craig, C HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS 1998 9764779 Yes 718 Winters, MA A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998 9819361 Yes 726 Tisdale, M Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. AAC 1997 9145875 Yes 728 Young, SD L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. AAC 1995 8592986 Yes 730 Larder, BA 3'-Azido-3'-Deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. AAC 1992 1282792 Yes 732 Richman, DD Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. PNAS 1991 1722324 Yes 738 Kellam, P Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. PNAS 1992 1371886 Yes 742 Palmer, S Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 1999 10397560 Yes 746 Carrillo, A In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378. J Virol 1998 9696850 Yes 751 Partaledis, JA In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995 7636964 Yes 755 Zolopa, AR HIV-1 genotypic resistance patterns predict response to saquinavir/ritonavir in patients in whom previous protease inhibitor therapy failed. Ann Intern Med 1999 10610625 Yes 756 Shulman, NS Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response. JAIDS 2000 10839657 Yes 758 Tisdale, M Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. AAC 1995 7486905 Yes 763 Deeks, SG Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999 10228057 Yes 768 Larder, BA A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. AAC 1999 10428920 Yes 782 Fujiwara, T S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. AAC 1998 9624472 Yes 789 Imamichi, T High-level resistance to 3'-azido-3'-deoxythymidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J Virol 2000 10623768 Yes 792 Pellegrin, I Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. AIDS 1999 10509572 Yes 807 Petropoulos, CJ A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. AAC 2000 10722492 Yes 808 Falloon, J Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis 2000 10671334 Yes 810 Hertogs, K A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. AAC 2000 10681319 Yes 813 Ziermann, R A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol 2000 10756056 Yes 817 Miller, V HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000 10708287 Yes 822 Lennerstrand, J Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. AAC 2001 11408240 Yes 823 Sevin, AD Methods for investigating the relationship between drug-susceptibility phenotype and HIV-1 genotype with applications to ACTG 333. J Infect Dis 2000 10882582 Yes 825 Huang, W A novel HIV-1 RT mutation (M230L) confers NNRTI resistance and dose-dependent stimulation of replication. Antivir Ther 2000 Yes 840 Huang, W Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol 2003 12502865 Yes 845 Gong, YF In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. AAC 2000 10952574 Yes 848 Huang, W Complex interactions involving multiple amino acid substitutions alter NNRTI susceptibility. Antivir Ther 1999 Yes 850 Whitcomb, J Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: Clinical, phenotypic and genotypic correlates. AIDS 2002 12370521 Yes 852 Jorgensen, LB Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine. Antivir Ther 2000 11075938 Yes 853 Vergne, L Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000 11060045 Yes 857 Parkin, NT Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS 2000 11153669 Yes 864 Parkin, NT Discordance between genotype-based predictions of protease inhibitor susceptibility and actual phenotype in HIV-1 isolates containing mutations at positions 82 and 90: Modulatory effects of mutations at secondary positions. ICAAC 2000 2001 Yes 865 Brun, S Patterns of protease inhibitor cross resistance in viral isolates with reduced susceptibility to lopinavir. CROI 2001 2001 Yes 869 Maguire, M Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: Selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. AAC 2002 11850255 Yes 870 Gonzales, MJ HIV-1 reverse transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis 2001 11574914 Yes 874 Walter, H Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy. Antivir Ther 2000 11142619 Yes 879 Bacheler, LT Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001 11333879 Yes 891 Van Laethem, K Patient HIV strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. AIDS 2000 10770556 Yes 893 Parkin, NT Genotypic and phenotypic analysis of a large database of patient samples reveals distinct patterns of protease inhibitor cross-resistance. Antivir Ther 2001 000000 Yes 906 Kempf, DJ Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001 11462018 Yes 913 Zachary, KC Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo. Clin Infect Dis 2001 11700580 Yes 948 Qari, SH Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J Clin Microbiol. 2002 11773089 Yes 951 Gonzales, MJ Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003 12660525 Yes 952 Colonno, RJ Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004 15122516 Yes 953 Margot, NA Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002 12045487 Yes 960 Wu, TD Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003 12663790 Yes 967 Dunne, AL Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 2001 11504978 Yes 968 Ait-Khaled, M Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine, zidovudine in HIV-1 infected adults with no prior antiretroviral therapy. Antivir Ther 2002 12008787 Yes 998 Parkin, NT Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. AAC 2003 14742192 Yes 1024 Roge, BT K65R with and without S68: A new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther 2003 12741630 Yes 1027 Gonzales, MJ Protease and reverse transcriptase mutation patterns in HIV-1 isolates from heavily treated persons: Comparison of isolates from northern California with isolates from other regions. ARHR 2003 14601580 Yes 1028 Condra, JH In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995 7700387 Yes 1029 Johnston, E Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. AAC 2004 15561868 Yes 1031 Harrigan, PR A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J Virol 2002 12050397 Yes 1033 Dumans, AT Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naive human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. AAC 2002 12183276 Yes 1035 Mo, H Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to HIV protease inhibitors and impair viral replication. AAC 2006 17101675 Yes 1036 Miller, MD Characterization of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF or stavudine and efavirenz. Antivir Ther 2003 Yes 1039 Romano, L Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J Infect Dis 2002 11920313 Yes 1040 Dauber, DS Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J Virol 2002 11773410 Yes 1042 Winters, MA Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs. AAC 2001 11451685 Yes 1044 Harrigan, PR Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2005 15802972 Yes 1053 Sevigny, G Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor. Antiviral Res 2006 16473417 Yes 1054 Parkin, NT HIV-1 reverse transcriptase mutations that suppress zidovudine resistance also increase in vitro susceptibility to tenofovir, but not stavudine. IHDRW 2003 2003 Yes 1056 Prado, JG Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002 11953467 Yes 1058 Masquelier, B Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. AAC 2001 11353634 Yes 1062 Kagan, RM Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci 2005 15937277 Yes 1063 Srinivas, RV Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. AAC 1998 9624498 Yes 1064 Harrigan, PR Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 1996 8709214 Yes 1065 Wainberg, MA In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999 10682153 Yes 1066 Foli, A In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-{2-(phosphonomethoxy)ethyl}adenine (PMEA). Antiviral Res 1996 8891168 Yes 1079 Bellosillo, N G190A substitution is associated with delavirdine(DLV) hypersusceptibility in vitro and clinical response with DLV intensification. Antivir Ther 2003 Yes 1091 Vidal, C Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine. Antivir Ther 2002 12553483 Yes 1092 Monno, L HIV-1 phenotypic susceptibility to lopinavir(LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. JAIDS 2003 12869832 Yes 1102 Lanier, ER Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med 2004 15544690 Yes 1103 Shafer, RW Unpublished miscellaneous clinical isolates. Unpublished 2004 No 1123 Kuritzkes, DR Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. JAIDS 2004 15097303 Yes 1127 Grossman, Z Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. AAC 2004 15155216 Yes 1129 Gonzales, MJ Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing. JAIDS 2003 14615657 Yes 1130 Mueller, SM Susceptibility to saquinavir and atazanavir in highly protease inhibitor(PI) resistant HIV-1 is caused by lopinavir-induced drug resistance mutation L76V. Antivir Ther 2004 Yes 1131 Sevigny, G Cross-resistance profile of the novel lysine-containing HIV-1 protease inhibitor PL-100. IHDRW 2004 2004 Yes 1132 Vergne, L Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS 2003 14565607 Yes 1133 Yates, PJ In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385. AAC 2006 16495277 Yes 1134 Delgado, J Genotypic (and phenotypic) predictors of a response to DDI monotherapy in ZDV-experienced patients. Antivir Ther 2004 Yes 1148 Murphy, MD HIV protease mutations associated with amprenavir resistance during salvage therapy: Importance of I54M. J Clin Virol 2004 15072756 Yes 1150 Lam, E Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation. Clin Infect Dis 2003 14557976 Yes 1151 Friend, J Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004 15353986 Yes 1153 Rhee, SY Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. AAC 2004 15273130 Yes 1155 Holguin, A Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 2004 15465415 Yes 1166 Winters, MA Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors. J Virol 2000 11044115 Yes 1167 Rhee, SY HIV-1 protease and reverse transcriptase mutations: Correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 2005 15995959 Yes 1168 Johnston, E Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations. AIDS 2005 15821401 Yes 1202 Coakley, E Atazanavir resistance in a protease inhibitor-naive patient treated with atazanavir/ritonavir associated with development of high-level atazanavir resistance and the N88S mutation in protease. CROI 2007 2005 Yes 1210 Mo, H Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol 2005 15731227 Yes 1251 Vidal, N HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). ARHR 2006 16478404 Yes 1253 Agwale, SM Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. ARHR 2006 16438641 Yes 1259 Parkin, NT The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. AAC 2006 16377709 Yes 1263 Doyon, L Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res 2005 16122817 Yes 1265 Ross, LL A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine. AIDS 2006 16514317 Yes 1266 Resch, W Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir. J Virol 2005 16051856 Yes 1267 Shafer, RW Miscellaneous Clinical Isolates. Unpublished 2006 No 1278 Vergne, L Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol 2006 16563858 Yes 1285 Rhee, SY Genotypic predictors of human immunodeficiency virus type 1 drug resistance. PNAS 2006 17065321 Yes 1485 Baxter, JD Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006 16928764 Yes 1495 Ochoa de Echaguen, A Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. AIDS 2005 16103769 Yes 1497 Jones, G Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). . CROI 2007 2007 Yes 1513 Malan, DR 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. J Int Assoc Physicians AIDS Care 2010 20071596 Yes 1514 Zolopa, A Resistance profile after viral rebound on atazanavir-containing therapy: focus on protease inhibitor naive subjects in the IMPACT study (BMS AI424-128). IHDRW 2007 2007 Yes 1516 Andries, K TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. AAC 2004 15561844 Yes 1517 Das, K Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004 15115397 Yes 1518 Vingerhoets, J TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005 16188980 Yes 1519 Su, G In vitro selection and characterization of viruses resistant to R1206, a novel nonnucleoside reverse transcriptase inhibitor. IHDRW 2007 2007 Yes 1539 King, M Phenotypic susceptibility to TMC-114 and tipranavir before and after lopinavir/ritonavir-based treatment in subjects demonstrating evolution of lopinavir resistance. IHDRW 2006 2006 Yes 1542 Bradshaw, D Characterization of a novel drug-resistance pattern associated with the mutations K70G and M184V in HIV-1 reverse transcriptase. AAC 2007 17876005 Yes 1578 Shimura, K Broad anti-retroviral activity and resistance profile of a novel human immunodeficiency virus integrase inhibitor, Elvitegravir (JTK-303/GS-9137). J Virol 2007 17977962 Yes 1581 Eshleman, SH Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations. ARHR 2006 16545016 Yes 1604 Ren, C In vitro cross-resistance studies of five different classes of integrase inhibitors in recombinant HIV-1. Antivir Ther 2007 Yes 1605 Rowley, M The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection. Prog Med Chem 2008 18381123 Yes 1610 Hombrouck, A Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. AAC 2008 18378713 Yes 1620 Poveda, E Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 2008 18317002 Yes 1643 Goethals, O Resistance mutations in HIV-1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008 18715920 Yes 1645 Vingerhoets, J An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): Multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. IHDRW 2008 2008 Yes 1646 De Meyer, S Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 2009 19474650 Yes 1649 Das, K High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations. PNAS 2008 18230722 Yes 1664 Poveda, E Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS 2008 18981781 Yes 1665 Jones, GS Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. AAC 2009 19104010 Yes 1672 Eshleman, SH Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. AIDS 2009 19276794 Yes 1684 Van Baelen, K A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes. J Virol Methods 2009 19559730 Yes 1692 Fransen, S HIV-1 mutations at positions 143, 148, and 155 of integrase define different genetic barriers to raltegravir resistance in vivo. Journal of Virology 2012 22553340 Yes 1718 Vingerhoets, J Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010 20051805 Yes 1719 Reuman, EC Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. AAC 2010 19917747 Yes 1745 Azijn, H TMC278, a next-generation NNRTI, active against wild-type and NNRTI-resistant HIV-1. AAC 2010 19933797 Yes 1746 Saskova, KG Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir. J Virol 2009 19535439 Yes 1752 Kagan, RM Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase. Antiviral Res 2007 17442410 Yes 1757 Maiga, AI Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naive patients infected with non-B HIV-1 subtypes. AAC 2010 20008779 Yes 1763 Low, A Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. AAC 2009 19651917 Yes 1790 Rhee, SY HIV-1 protease mutations and protease inhibitor cross resistance. AAC 2010 20660676 Yes 1793 Goethals, O Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 2010 20421122 Yes 1795 Underwood, M The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. JAIDS 2012 22878423 Yes 1796 da Silva, D HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 2010 20388636 Yes 1800 Fransen, S Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009 19759152 Yes 1950 Kagan, RM Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples. AIDS 2009 19474648 Yes 1957 Tambuyzer, L Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir Ther 2009 19320243 Yes 1958 Balamane, M Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine. AAC 2012 22664973 Yes 1960 Hu, Z Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase. JAIDS 2007 17496561 Yes 1961 Kulkarni, R The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. JAIDS 2012 21997204 Yes 1963 Varghese, V Phenotypic evidence for NRTI resistance in HIV-1 isolates with the RT mutation K64H. Unpublished 2011 Yes 1995 Gupta, S Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens AAC 2011 21464253 Yes 1997 Melikian, GL Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility. AAC 2012 22330916 Yes 2001 Margot, NA In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4 Antiviral Res 2012 22197635 Yes 2004 Haddad, M Mutation Y188L of HIV-1 reverse transcriptase is strongly associated with reduced susceptibility to rilpivirine CROI 2012 2011 Yes 2006 Li, Z The in vitro cross-resistance profile of the NRTI BMS-986001 against known NRTI resistance mutations IWHHVDR 2012 2012 Yes 2007 Abram, ME Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. AAC 2013 23529738 Yes 2008 Garrido, C Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. AAC 2012 22450969 Yes 2014 Blanco, JL Residual Antiviral Activity of Raltegravir in Patients with Resistance Mutations: A Prospective Study (RAL-dyn Study) unpublished 2012 No 2025 Varghese, V Panel of Prototypical Recombinant Multi-Protease Inhibitor Resistant Infectious Molecular Clones unpublished 2012 Yes 2041 Villena, C Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region. J Virol 2007 17314158 Yes 2045 Sato, A In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Antiviral Res 2006 16472877 Yes 2087 Gatanaga, H Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine. AAC 2010 20124001 Yes 2090 Van Wesenbeeck, L Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. AAC 2011 20956600 Yes 2092 Canducci, F Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 2011 21984737 Yes 2099 Mesplede, T Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 2013 23432922 Yes 2100 Malet, I The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother 2011 21933786 Yes 2105 McColl, DJ Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy. Antiviral Res 2010 19925830 Yes 2110 Van Eygen, V Comparison of the Antivirogram and PhenoSense assays to determine phenotypic susceptibility to rilpivirine in patient samples from the Phase III ECHO and THRIVE trials. International Workshop on HIV & Hepatitis Virus 2012 Yes 2113 Armenia, D Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: A refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis 2012 22238474 Yes 2114 Melikian, GL Nonnucleoside RT inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother 2013 23934770 Yes 2117 Porter, DP Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110) JAIDS 2014 24525469 Yes 2119 Huang, W Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir. AAC 2013 23733474 Yes 2131 Haddad, M Combinations of HIV-1 reverse transcriptase mutations L100I+K103N/S and L100I+K103R+V179D reduce susceptibility to rilpivirine. Interscience Conference on Antimicrobial Agents an 2013 Yes 2137 Xu, HT Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors. AAC 2013 24002090 Yes 2214 Hardy, I Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother 2015 25281399 Yes 2226 Molina, JM Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012 22015077 Yes 2227 Sax, PE Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012 22748591 Yes 2228 DeJesus, E Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012 22748590 Yes 2262 Anstett, K Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions. J Virol 2015 25653436 Yes 2263 Anstett, K Dolutegravir-selected HIV-1 containing the N155H and R263K resistance substitutions does not acquire additional compensatory mutations under drug pressure that lead to higher-level resistance and increased replicative capacity. J Virol 2015 26246578 Yes 2264 Yoshinaga, T Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. AAC 2015 25367908 Yes 2265 Cutillas, V The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir. AAC 2015 25348535 Yes 2266 Liang, J The combination of the R263K and T66I resistance substitutions in HIV-1 integrase is incompatible with high-level viral replication and the development of high-level drug resistance. J Virol 2015 26311878 Yes 2267 Mesplede, T Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother 2014 24917583 Yes 2304 Hachiya, A Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance. Antiviral Res 2015 25956162 Yes 2347 Salgado, M Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J Clin Virol 2009 19625211 Yes 2465 Deuzing, IP Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses. J Virol 2015 25355888 Yes 2470 Abram, ME Pre-existing HIV-1 integrase polymorphisms do not impact treatment response to elvitegravir-containing fixed-dose combination regimens in treatment-naive patients. HIV Drug Therapy 2016 Glasgow 2016 Yes 2479 Brenner, BG Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. J Antimicrob Chemother 2016 27029845 Yes 2512 Raugi, DN Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy. Antimicrob Agents Chemother 2013 23571535 Yes 2591 Andreatta, K Integrase Inhibitor Resistance Selections Initiated with Drug Resistant HIV-1. CROI 2018 Yes 2592 Tsiang, M Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother 2016 27645238 Yes 2593 Hassounah, SA Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1. Antimicrob Agents Chemother 2017 28923862 Yes 2596 Smith, SJ Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology 2018 29769116 Yes 2598 White, K Bictegravir Resistance Profile: Data for External Experts. Unpublished 2018 Yes 2599 Hachiya, A Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors. Antimicrob Agents Chemother 2017 28533248 Yes 2600 Yoshinaga, T Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors. Antiviral Res 2018 29410019 Yes 2601 Vavro, C Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572). Antimicrob Agents Chemother 2013 23295935 Yes 2602 Anstett, K Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity. J Antimicrob Chemother 2016 27084918 Yes 2603 Quashie, PK Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J Virol 2015 25552724 Yes 2604 Malet, I Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance. J Antimicrob Chemother 2018 29373677 Yes 2605 Malet, I New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother 2014 24710029 Yes 2607 Wares, M The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 2014 24433497 Yes 2608 Quashie, PK Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012 22205735 Yes 2609 Pham, HT The S230R Integrase Substitution Associated with Viral Rebound during DTG Monotherapy Confers Low Levels INSTI Drug Resistance. J Infect Dis 2018 29617824 Yes 2610 Malet, I Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. J Antimicrob Chemother 2015 26205139 Yes 2612 Vavro, C Evolution of HIV-1 Integrase Following Selection of R263K With Further Dolutegravir Treatment: A Case Report From the P1093 Study. IAS 2015 No 2613 Munir, S G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance. J Antimicrob Chemother 2015 25414202 Yes 2616 Zhang, WW Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors. J Infect Dis 2018 30010985 Yes 2617 Charpentier, C Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. J Antimicrob Chemother 2018 29342281 Yes 2618 Seki, T Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro. Antimicrob Agents Chemother 2015 25691633 Yes 2619 Saladini, F The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro. AIDS 2017 28832412 Yes 2620 Mesplede, T The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. AIDS 2015 26244385 Yes 2621 Varghese, V Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility. ARHR 2016 27009474 Yes 2622 George, JM Rapid development of high level resistance to dolutegravir with emergence of T97A mutation in two treatment experienced individuals with baseline partial sensitivity to dolutegravir. Open Forum Infect Dis 2018 30568974 Yes 2623 Oliveira, M Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology 2018 30119633 Yes 2624 Vavro, C Emergence of resistance in HIV-1 Integrase (IN) following dolutegravir (DTG) treatment in 6 to 18 year old participants enrolled in the P1093 study. IAS 2018 No 2628 Lai, MT In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2014 24379202 Yes 2629 Lai, MT Characterization of Doravirine-Selected Resistance Patterns From Participants in Treatment-Naive Phase 3 Clinical Trials. IAC 2018 Yes 2642 Shahid, A Systematic determination of in vitro phenotypic resistance to HIV-1 integrase strand transfer inhibitors from clinical samples bioRxiv 2019 Yes 2691 Andreatta, K HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro. JAIDS 2013 23187937 Yes 2692 Masse, S In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Antimicrob Agents Chemother 2007 17576848 Yes 2693 Ntemgwa, M Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother 2007 17116674 Yes 2694 Smith, RA Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis 2009 19358668 Yes 2695 Smith, RA Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. PLoS ONE 2012 23028968 Yes 2696 Le Hingrat, Q A new mechanism of resistance of HIV-2 to integrase inhibitors: a 5 amino-acids insertion in the integrase C-terminal domain. Clin Infect Dis 2018 30383215 Yes 2697 Raugi, DN Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors. J Virol 2016 26559830 Yes 2698 Smith, RA Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. AIDS 2011 21971360 Yes 2699 Smith, RA In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2. Retrovirology 2015 25808007 Yes 2809 Feng, M In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother 2015 25385110 Yes 2810 Feng, M Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations. Antimicrob Agents Chemother 2016 26833152 Yes 2811 Smith, SJ Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants. JAIDS 2016 27124362 Yes 2812 Hazuda, DJ Understanding the Resistance Profile of the HIV-1 NNRTI Doravirine in Combination With the Novel NRTTI MK-8591. IAC 2018 Yes 2853 Margot, NA Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naive individuals. J Med Virol 2019 31389026 Yes 2859 Saladini, F Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations. Antimicrob Agents Chemother 2019 31611362 Yes 2870 Desbois, D In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008 18227188 Yes 2872 Smith, RA Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants. Antimicrob Agents Chemother 2019 30803972 Yes 2974 Grobler, JA Efficacy of MK-8591 against diverse HIV-1 subtypes and NRTI-resistant clinical isolates. HIV Glasgow Conference 2018 Yes 3010 Rizzardini, G Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. J Acquir Immune Defic Syndr 2020 33136751 Yes 3011 Smith, SJ HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants. Antimicrob Agents Chemother 2020 32601157 Yes 3013 Ndashimye, E Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. J Antimicrob Chemother 2020 32853364 Yes 3014 Santoro, MM Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. Int J Antimicrob Agents 2020 32450199 Yes 3025 Overton, ET Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet 2021 33308425 Yes 3029 van Wyk, J Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials. J Acquir Immune Defic Syndr 2020 32675772 Yes 3033 Gandhi, RT Long-term Outcomes in a Large Randomized Trial of HIV-1 Salvage Therapy: 96-Week Results of AIDS Clinical Trials Group A5241 (OPTIONS). J Infect Dis 2020 31135883 Yes 3037 Ndashimye, E High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations. J Antimicrob Chemother 2021 34453542 Yes 3055 Cheung, PK Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study. J Antimicrob Chemother 2022 35061879 Yes 3063 Jeffrey, JL Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine. Antimicrob Agents Chemother 2022 34978890 Yes 3083 Brenner, BG Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir. J Antimicrob Chemother 2021 33855437 Yes 3102 Underwood, M Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study. Antimicrob Agents Chemother 2022 34694877 Yes 3106 Smith, RA Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants. J Infect Dis 2022 35134180 Yes 3113 Vavro, C Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study. Antimicrob Agents Chemother 2022 34694878 Yes 3122 Rimsky, L Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2012 22067667 Yes 3135 Puertas, MC Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report. Lancet Microbe 2020 35544263 Yes 3136 Eshleman, SH HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention. J Infect Dis 2022 36240386 Yes 3197 van Kampen, JJA HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report. J Glob Antimicrob Resist 2022 36347497 Yes 3227 Martin, EA Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development. J Acquir Immune Defic Syndr 2020 32925358 Yes 3230 Diamond, TL Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Antimicrob Agents Chemother 2022 35546110 Yes 3267 Brenner, BG Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure. J Antimicrob Chemother 2023 37303226 Yes